N/A N=99 Inflammatory Abnormalities in Muscle After Stroke: Effects of Exercise
Stroke · Inflammation
Primary: Cardiovascular Fitness (VO2 Peak) — 15.9; 16.6; 21.3; 17.5 ml/kg/min — p=0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=34 Efficacy of a Controlled Short-term Trial of Cannabidiol (CBD) Ingestion on Reducing Symptomatic Response and Facilitating Recovery After Induced Muscle Injury
Muscle Injury · Recovery · Pain Relief
Primary: Self-report Ratings of Muscle Soreness — 0.0; 0.0 score on a scale
N/A N=17 Musculotendinous Tissue Repair Unit and Reinforcement (MTURR)
Traumatic Injury · Muscle Injury · Tendon Injury
Primary: Percent Change From Baseline in the Rectified and Integrated EMG Signal of the Tibialis Anterior Muscle At 24 Weeks Post-Operative — 1333 % change
N/A N=40 Ultrasound in Muscle Biopsy
Myopathy · Myositis · Muscular Dystrophy
Primary: Amount of Tissue Obtained — 0.29; 0.28 grams
N/A N=38 Strength Training for Skeletal Muscle Adaptation After Stroke
Stroke
Primary: Change in 1-repetition Maximum (RM) Muscle Strength (Leg Press, Paretic Side) — 126.1; 11.3 lbs
Phase 2 N=25 Prevention of Skeletal Muscle Adaptations to Traumatic Knee Injury and Surgery
Anterior Cruciate Ligament Reconstruction
Primary: Cross-sectional Area of Skeletal Muscle Fibers (All Fibers) — 2827; 3318; 2206; 2376 micrometer squared — p=<0.05
N/A N=105 Prevention of Musculoskeletal Injuries in Slovenian Armed Forces
Knee Injuries and Disorders · Ankle Injuries and Disorders · Low Back Pain
Primary: Number of Soldiers With Ankle and Knee Injuries — 1; 3 Participants — p=0.134
N/A N=37 Forearm Immobilization, Metabolic Health, and Muscle Loss
Healthy
Primary: Percent Change in Forearm Glucose Uptake — -73; 127; -95 Percent change in clamp FGU with immob
N/A N=71 Musculoskeletal Plasticity After Spinal Cord Injury
Spinal Cord Injuries
Primary: Acute Gene Regulation: MSTN — 5.49; 4.76 arbitrary units — p=<0.001
Phase 3 N=116 Platelet Rich Plasma in Levator Ani Muscle Trauma
Pelvic Floor Disorders
Primary: Changes of Levator Hiatal Area During Valsava — 20.64; 20.35; 22.35; 21.41 Cm2 — p=0.086
N/A N=38 Training Induced Muscle Exosome Release
Metabolism
Primary: miR-1 Abundance — 226; 110; 286 percent change
N/A N=33 Novel Intervention to Influence Muscle Plasticity in Veterans
Spinal Cord Injuries
Primary: HF Muscle Force — 23.9; 30.9 Newtons (N)
Phase 3 N=205 Topical Ibuprofen for Delayed Onset Mulscle Soreness
Pain
Primary: Change From Baseline in the Time-Weighted Sum of Muscle Soreness With Movement Over 0-24 Hours Post-Dose 1 (MSM 0-24 ) — 22.2; 17.8; 29.7 units on a scale — p=0.200
N/A N=8 7 Tesla MRI Study in Patients With Statin Related Muscle Complaints
Statin-related Muscle Pain · Muscle Aches · Muscle Weakness
Primary: Change in Pre- and Post-phosphocreatine Relaxation Time — 5.58; 5.083 milliseconds
N/A N=12 Impact of Muscle Temperature on Muscle Growth and Breakdown: Cooling During Resistance Training
Exercise Training
Primary: RT-qPCR for Forkhead Box O3 (FOXO3a) — 1.24; 1.30 fold change — p=.609
N/A N=23 Skeletal Muscle Atrophy and Dysfunction Following Total Knee Arthroplasty
Knee Osteoarthristis
Primary: Cross-sectional Area (CSA) of Muscle Fibers — 2680; 2377; 2028; 1882 micron squared
N/A N=62 Serial Movement Assessment in Collegiate Athletes Who Perform Injury Prevention Training
Injury Leg · Injury, Knee · Injury;Sports
Primary: Landing Error Scoring System (LESS) Score — 6; 5.8; 5.2 errors
N/A N=22 Diagnosing Intensive Care Unit (ICU) Acquired Weakness
ICU Acquired Weakness
Primary: Peak Acceleration Measured in Extensor Carpi Radialis Longus — 0.476; 1.639; 0.541; 1.608 units of Gravity
N/A N=68 Blood Flow, Muscle Regeneration and Sarcopenia
Sarcopenia
Primary: Muscle Satellite Cells — 3.2; 3.2; 4.0; 3.8 Number of Pax7+ cells/muscle fiber
Phase 2 N=20 Safety and Efficacy of IM Injections of PLX-PAD for the Regeneration of Injured Gluteal Musculature After Total Hip Arthroplasty
Total Hip Arthroplasty · Muscle Injury
Primary: Change From Day 0 to Week 26 in the Maximal Voluntary Isometric Contraction (MVIC) Moment of the Injured Side to Assess Gluteus Medius Strength. — 31.17; 20.36; 5.43…
N/A N=42 Quantifying Myofascial Dysfunction in Post-Stroke Pain
Myofascial Dysfunction
Primary: T1 Rho MRI Relaxation Time of Shoulder External Rotator (Milliseconds) — 29.09; 27.15 milliseconds
N/A N=40 E-Stim and Achilles Tendon Repair Study
Achilles Tendon Rupture
Primary: Reduce Calf Muscle Atrophy — 859.8; 874.9; 1450.4; 1634.9 mm^2
N/A N=12 Inflammation and Protein Restriction
Protein Restriction · Diet · Inflammation
Primary: Changes in the Human Intestinal Microbiome That Result From Short Term Dietary Adjustment. — 232; 172; 145; 93 Number of immunity related genes — p=0.05
N/A N=17 Palliative Strategies in Spinal Cord Injury (SCI)
Spinal Cord Injury
Primary: Muscle Mass Via Dual-Energy X-ray Absortiometry (DEXA)Scan Data — 6104.45; 6355.3 grams — p=.318
N/A N=16 Effect of Exercise on the Human Skeletal Muscle Phosphoproteome
Skeletal Muscle Protein Synthesis
Primary: Change in Acute Muscle Protein Synthesis — 143; 123 percent change
N/A N=20 Preventing the Loss of Muscle and Function in Hospitalized Older Adults
Muscular Atrophy
Primary: The Percent Change in Bilateral Thigh Lean Mass Density (Grams) as Measured by DEXA Scan Will be Compared Between Baseline and After 5-days of Bed Rest — -3.845; -0.249…
N/A N=40 Muscle Regrowth During Physical Rehabilitation and Amino Acid Supplementation
Osteoarthritis
Primary: Stair Time up — 7; 8 seconds
N/A N=14 Vascular Dysfunction During Physical Inactivity
Aging · Vascular Endothelium · Skeletal Muscle
Primary: Brachial Artery Vascular Function — 5.1; 3.1; 4.4 percent vasodilation
N/A N=30 Muscle Fatigue and Scapular Sensorimotor System
Muscle; Fatigue
Primary: Change From Baseline in Scapular Proprioception — -0.48; -0.19; -0.37; -0.32 centimeters — p=0.227
N/A N=24 Spinal Cord Injury - Exercise
Spinal Cord Injuries
Primary: Effect of Exercise on Inflammation (C-reactive Protein) — 0.00; 0.05 mg/dL